Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives Additional Orphan Drug Designation for Hemophilia Drug

Premium

Alnylam Pharmaceuticals this week announced that it has received an orphan drug designation from the US Food and Drug Administration for its preclinical siRNA-based drug ALN-AT3 as a treatment for hemophilia A.

Last week, the company said that the drug received an orphan drug designation from the FDA for hemophilia B.

The designation provides a drugmaker with, among other things, extended market exclusivity for its product, tax credits, and marketing incentives.

ALN-AT3 is expected to enter phase I testing next year.